NASDAQ: ACHV
Achieve Life Sciences Inc Stock

$3.37-0.16 (-4.53%)
Updated Feb 11, 2025
ACHV Price
$3.37
Fair Value Price
-$0.06
Market Cap
$115.89M
52 Week Low
$2.84
52 Week High
$5.59
P/E
-3.04x
P/B
3.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$32.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.53
Operating Cash Flow
-$25M
Beta
0.79
Next Earnings
Mar 26, 2025
Ex-Dividend
N/A
Next Dividend
N/A

ACHV Overview

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine ACHV's potential to beat the market

FStrong Sell
  • Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More

Zen Rating Component Grades

C
Value
D
Growth
D
Momentum
C
Sentiment
D
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
ACHV
Ranked
#512 of 558

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important ACHV news, forecast changes, insider trades & much more!

ACHV News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACHV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACHV ($3.37) is overvalued by 5,738.67% relative to our estimate of its Fair Value price of -$0.06 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ACHV ($3.37) is not significantly undervalued (5,738.67%) relative to our estimate of its Fair Value price of -$0.06 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACHV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACHV due diligence checks available for Premium users.

Valuation

ACHV fair value

Fair Value of ACHV stock based on Discounted Cash Flow (DCF)

Price
$3.37
Fair Value
-$0.06
Undervalued by
5,738.67%
ACHV ($3.37) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACHV ($3.37) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACHV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ACHV price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-3.04x
Industry
-137.9x
Market
31.02x

ACHV price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
3.69x
Industry
4.8x
ACHV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACHV's financial health

Profit margin

Revenue
$0.0
Net Income
-$12.5M
Profit Margin
0%
ACHV's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$47.9M
Liabilities
$16.5M
Debt to equity
0.53
ACHV's short-term assets ($45.53M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACHV's short-term assets ($45.53M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACHV's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACHV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$10.4M
Investing
$13.3M
Financing
-$8.1M
ACHV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ACHV vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
ACHVF$115.89M-4.53%-3.04x3.69x
MISTC$116.79M-1.79%-2.70x4.86x
RENBF$117.13M-1.99%-0.87x1.19x
VTYXD$114.55M-2.99%-0.69x0.41x
CRBUD$114.10M-4.55%-0.76x0.41x

Achieve Life Sciences Stock FAQ

What is Achieve Life Sciences's quote symbol?

(NASDAQ: ACHV) Achieve Life Sciences trades on the NASDAQ under the ticker symbol ACHV. Achieve Life Sciences stock quotes can also be displayed as NASDAQ: ACHV.

If you're new to stock investing, here's how to buy Achieve Life Sciences stock.

What is the 52 week high and low for Achieve Life Sciences (NASDAQ: ACHV)?

(NASDAQ: ACHV) Achieve Life Sciences's 52-week high was $5.59, and its 52-week low was $2.84. It is currently -39.71% from its 52-week high and 18.66% from its 52-week low.

How much is Achieve Life Sciences stock worth today?

(NASDAQ: ACHV) Achieve Life Sciences currently has 34,389,946 outstanding shares. With Achieve Life Sciences stock trading at $3.37 per share, the total value of Achieve Life Sciences stock (market capitalization) is $115.89M.

Achieve Life Sciences stock was originally listed at a price of $1,311,947.87 in Dec 31, 1997. If you had invested in Achieve Life Sciences stock at $1,311,947.87, your return over the last 27 years would have been -100%, for an annualized return of -37.92% (not including any dividends or dividend reinvestments).

How much is Achieve Life Sciences's stock price per share?

(NASDAQ: ACHV) Achieve Life Sciences stock price per share is $3.37 today (as of Feb 11, 2025).

What is Achieve Life Sciences's Market Cap?

(NASDAQ: ACHV) Achieve Life Sciences's market cap is $115.89M, as of Feb 12, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Achieve Life Sciences's market cap is calculated by multiplying ACHV's current stock price of $3.37 by ACHV's total outstanding shares of 34,389,946.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.